Overview

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Status:
Terminated
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to test the safety of combination treatment with Avelumab and Decitabine in newly diagnosed AML patients who are unfit for intensive induction chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborator:
Pfizer
Treatments:
Avelumab
Decitabine